Coagulazione, infiammazione e CVD

Titolo	Data creazione	Visite
Reversion from prediabetes to normoglycaemia and risk of cardiovascular disease and mortality: the Whitehall II cohort study	13 Giugno 2019	Visite: 38
Differences in Carotid Plaques Between Symptomatic Patients With and Without Diabetes Mellitus A CARE-II Study	21 Maggio 2019	Visite: 73
Cardiovascular Risk Factor Burden in People With Incident Type 2 Diabetes in the U.S. Receiving Antidiabetic and Cardioprotective Therapies	18 Aprile 2019	Visite: 82
Empagliflozin enhances human and murine cardiomyocyte glucose uptake by increased expression of GLUT1	26 Marzo 2019	Visite: 112
Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study	18 Febbraio 2019	Visite: 98
Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure. Benefits of SGLT2 Inhibitors	25 Gennaio 2019	Visite: 142
One quarter of total myocardial infarctions are silent manifestation in patients with type 2 diabetes mellitus	28 Dicembre 2018	Visite: 132
Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. The TOPCAT Trial	30 Novembre 2018	Visite: 98
Prolonged Prothrombotic Effects of Antecedent Hypoglycemia in Individuals With Type 2 Diabetes	02 Novembre 2018	Visite: 148
Mitochondrial oxidative stress, endothelial function and metabolic control in patients with type II diabetes and periodontitis: A randomised controlled clinical trial	09 Ottobre 2018	Visite: 110

Pagina 1 di 7

Ricerca

Cookie